Related Experiment Video
Updated: Jun 6, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Inhibiting TGF-β signaling in hepatocellular carcinoma
Gianluigi Giannelli1, Antonio Mazzocca, Emilia Fransvea
1Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine; University of Bari Medical School, Bari, Italy. g.giannelli@intmed.uniba.it
Abstract:
One of the main complications in patients with liver fibrosis is the development of hepatocellular carcinoma (HCC). An understanding of the molecular mechanisms leading to HCC is important in order to be able to design new pharmacological agents serving either to prevent or mitigate the outcome of this malignancy. The transforming growth factor-beta (TGF-β) cytokine and its isoforms initiate a signaling cascade which is closely linked to liver fibrosis, cirrhosis and subsequent progression to HCC. Because of its role in these stages of disease progression, TGF-β appears to play a unique role in the molecular pathogenesis of HCC. Thus, it is a promising target for pharmacological treatment strategies. Recent studies have shown that inhibition of TGF-β signaling results in multiple synergistic down-stream effects which will likely improve the clinical outcome in HCC. We also review a number of TGF-β inhibitors, most of which are still in a preclinical stage of development, but may soon be available for trial in HCC patients. Hence, it is anticipated that there will soon be new agents available for clinical investigations to evaluate the role of the TGF-β-associated signaling in this deadly cancer.
Insights
Transforming growth factor-beta (TGF-β) signaling is crucial in liver fibrosis and hepatocellular carcinoma (HCC) development. Inhibiting TGF-β shows promise for new pharmacological treatments to combat HCC.
Area of Science:
- Molecular biology
- Hepatology
- Oncology
Background:
- Liver fibrosis can progress to hepatocellular carcinoma (HCC), a significant clinical complication.
- Understanding the molecular drivers of HCC is essential for developing targeted therapies.
Purpose of the Study:
- To explore the role of transforming growth factor-beta (TGF-β) signaling in the pathogenesis of HCC.
- To review potential pharmacological strategies targeting TGF-β for HCC treatment.
Main Methods:
- Review of recent scientific literature on TGF-β signaling pathways in liver disease.
- Analysis of studies investigating the effects of TGF-β inhibition on HCC progression.
- Compilation of data on preclinical TGF-β inhibitors relevant to HCC.
Main Results:
- TGF-β signaling is intricately linked to liver fibrosis, cirrhosis, and the development of HCC.
- Inhibition of TGF-β signaling demonstrates synergistic downstream effects beneficial for HCC.
- Several TGF-β inhibitors are in preclinical development for potential HCC therapy.
Conclusions:
- TGF-β plays a critical role in the molecular pathogenesis of HCC, making it a promising therapeutic target.
- Inhibiting TGF-β signaling offers a potential strategy to improve clinical outcomes in HCC patients.
- New TGF-β-targeted agents are anticipated for future clinical trials in HCC.
More Related Videos
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
